HER2 mutant-selective inhibitor NVL-330

{
  "id": "MLC-T-ONC-014095",
  "term": "HER2 mutant-selective inhibitor NVL-330",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable mutant-selective inhibitor of the receptor tyrosine kinase human epidermal growth factor receptor 2 (HER2), with potential antineoplastic activity. Upon oral administration, HER2 mutant-selective inhibitor NVL-330 targets, binds to, and inhibits the activity of HER2 oncogenic alterations, including HER2 exon20 insertion mutations (exon20ins), HER2 activating point mutations, and amplified wild-type HER2. This prevents HER2-mediated signaling and may lead to cell death in HER2-expressing tumor cells. HER2, a receptor tyrosine kinase overexpressed on a variety of tumor cell types, plays an important role in tumor cell proliferation and tumor vascularization. NVL-330 is able to penetrate the blood-brain-barrier (BBB).",
  "synonyms": [
    "HER-2 mutant-selective inhibitor NVL-330"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/her2-mutant-selective-inhibitor-nvl-330/"
}